Cargando…

The Plasmodium falciparum chloroquine resistance transporter is associated with the ex vivo P. falciparum African parasite response to pyronaridine

BACKGROUND: The pyronaridine-artesunate combination is one of the most recent oral artemisinin-based therapeutic combinations (ACTs) recommended for the treatment of uncomplicated P. falciparum malaria. The emergence of P. falciparum resistance to artemisinin has recently developed in Southeast Asia...

Descripción completa

Detalles Bibliográficos
Autores principales:	Madamet, Marylin, Briolant, Sébastien, Amalvict, Rémy, Benoit, Nicolas, Bouchiba, Housem, Cren, Julien, Pradines, Bruno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746765/ https://www.ncbi.nlm.nih.gov/pubmed/26858119 http://dx.doi.org/10.1186/s13071-016-1358-z

Ejemplares similares

Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine
por: Pascual, Aurélie, et al.
Publicado: (2015)

Prevalence of mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, and association with ex vivo susceptibility to common anti-malarial drugs against African Plasmodium falciparum isolates
por: Foguim, Francis Tsombeng, et al.
Publicado: (2020)

In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter gene
por: Pascual, Aurélie, et al.
Publicado: (2013)

Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in Plasmodium falciparum
por: Pradines, Bruno, et al.
Publicado: (2010)

Prevalence of Mutations in the pfcoronin Gene and Association with Ex Vivo Susceptibility to Common Quinoline Drugs against Plasmodium falciparum
por: Delandre, Océane, et al.
Publicado: (2021)

Confirmation of Plasmodium falciparum in vitro resistance to monodesethylamodiaquine and chloroquine in Dakar, Senegal, in 2015
por: Diawara, Silman, et al.
Publicado: (2017)

The D113N mutation in the RING E3 ubiquitin protein ligase gene is not associated with ex vivo susceptibility to common anti-malarial drugs in African Plasmodium falciparum isolates
por: Gendrot, Mathieu, et al.
Publicado: (2018)

Plasmodium falciparum In Vitro Resistance to Monodesethylamodiaquine, Dakar, Senegal, 2014
por: Fall, Bécaye, et al.
Publicado: (2016)

Absence of Association between Methylene Blue Reduced Susceptibility and Polymorphisms in 12 Genes Involved in Antimalarial Drug Resistance in African Plasmodium falciparum
por: Gendrot, Mathieu, et al.
Publicado: (2021)

Low polymorphisms in pfact, pfugt and pfcarl genes in African Plasmodium falciparum isolates and absence of association with susceptibility to common anti-malarial drugs
por: Foguim, Francis Tsombeng, et al.
Publicado: (2019)

Influence of oxygen on asexual blood cycle and susceptibility of Plasmodium falciparum to chloroquine: requirement of a standardized in vitro assay
por: Briolant, Sébastien, et al.
Publicado: (2007)

Early treatment failure during treatment of Plasmodium falciparum malaria with atovaquone-proguanil in the Republic of Ivory Coast
por: Wurtz, Nathalie, et al.
Publicado: (2012)

Limited polymorphisms in k13 gene in Plasmodium falciparum isolates from Dakar, Senegal in 2012–2013
por: Torrentino-Madamet, Marylin, et al.
Publicado: (2014)

Assessment of a Commercial Real-Time PCR Assay (Vitassay qPCR Malaria 5 Test) to Detect Human Malaria Infection in Travelers Returning to France
por: Madamet, Marylin, et al.
Publicado: (2022)

Copper (I)-Chloroquine Complexes: Interactions with DNA and Ferriprotoporphyrin, Inhibition of β-Hematin Formation and Relation to Antimalarial Activity
por: Villarreal, Wilmer, et al.
Publicado: (2022)

Comparative Assessment of the Sensitivity of Ten Commercial Rapid Diagnostic Test Kits for the Detection of Plasmodium
por: Gendrot, Mathieu, et al.
Publicado: (2022)

In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum
por: Dormoi, Jérome, et al.
Publicado: (2014)

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria
por: Pryce, Joseph, et al.
Publicado: (2019)

Pyronaridine‐artesunate for treating uncomplicated Plasmodium falciparum malaria
por: Pryce, Joseph, et al.
Publicado: (2022)

Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum
por: Parquet, Véronique, et al.
Publicado: (2010)

Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum
por: Pascual, Aurélie, et al.
Publicado: (2012)

Metal-chloroquine derivatives as possible anti-malarial drugs: evaluation of anti-malarial activity and mode of action
por: Navarro, Maribel, et al.
Publicado: (2014)

Has doxycycline, in combination with anti-malarial drugs, a role to play in intermittent preventive treatment of Plasmodium falciparum malaria infection in pregnant women in Africa?
por: Gaillard, Tiphaine, et al.
Publicado: (2018)

Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria
por: Bukirwa, Hasifa, et al.
Publicado: (2014)

Chloroquine-Resistant Haplotype Plasmodium falciparum Parasites, Haiti
por: Londono, Berlin L., et al.
Publicado: (2009)

In vitro susceptibility to quinine and microsatellite variations of the Plasmodium falciparum Na(+)/H(+ )exchanger (Pfnhe-1) gene: the absence of association in clinical isolates from the Republic of Congo
por: Briolant, Sébastien, et al.
Publicado: (2011)

Return of chloroquine-sensitive Plasmodium falciparum parasites and emergence of chloroquine-resistant Plasmodium vivax in Ethiopia
por: Mekonnen, Seleshi Kebede, et al.
Publicado: (2014)

Prevalence of Plasmodium falciparum antimalarial drug resistance genes in Southeastern Gabon from 2011 to 2014
por: Voumbo-Matoumona, Dominique Fatima, et al.
Publicado: (2018)

Are k13 and plasmepsin II genes, involved in Plasmodium falciparum resistance to artemisinin derivatives and piperaquine in Southeast Asia, reliable to monitor resistance surveillance in Africa?
por: Foguim Tsombeng, Francis, et al.
Publicado: (2019)

The end of a dogma: the safety of doxycycline use in young children for malaria treatment
por: Gaillard, Tiphaine, et al.
Publicado: (2017)

Late clinical failure associated with cytochrome b codon 268 mutation during treatment of falciparum malaria with atovaquone–proguanil in traveller returning from Congo
por: Massamba, Laurencie, et al.
Publicado: (2020)

Plasmodium falciparum gametocyte dynamics after pyronaridine–artesunate or artemether–lumefantrine treatment
por: Roth, Johanna M., et al.
Publicado: (2018)

Efficacy and Safety of Pyronaridine–Artesunate for the Treatment of Uncomplicated Plasmodium falciparum and Plasmodium vivax Malaria in Myanmar
por: Han, Kay Thwe, et al.
Publicado: (2020)

On the Mechanism of Chloroquine Resistance in Plasmodium falciparum
por: Chinappi, Mauro, et al.
Publicado: (2010)

Chloroquine-resistant Plasmodium falciparum in Pakistan
por: Khattak, Aamer Ali, et al.
Publicado: (2021)

Plasmodium falciparum proteome changes in response to doxycycline treatment
por: Briolant, Sébastien, et al.
Publicado: (2010)

Global gene expression profiling of Plasmodium falciparum in response to the anti-malarial drug pyronaridine
por: Kritsiriwuthinan, Kanyanan, et al.
Publicado: (2011)

Plasmodium falciparum with Multidrug Resistance 1 Gene Duplications, Senegal
por: Pascual, Aurélie, et al.
Publicado: (2013)

Failure of dihydroartemisinin plus piperaquine treatment of falciparum malaria by under-dosing in an overweight patient
por: Roseau, Jean Baptiste, et al.
Publicado: (2016)

Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study
por: Fall, Bécaye, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_sj5us6059nsh73k3j2j6vnulh2